Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 17/20 | 0.77 |
| ▸ | KDM5A | P29375 | 5/20 | 0.77 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.71 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.67 |
| ▸ | KDM4A | O75164 | 1/20 | 0.60 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16075658 | 0.90 | KDM4C (0.80) | KDM4CKDM5AKDM2BKDM5BKDM4A | |
| SCHEMBL16034058 | 0.87 | KDM4C (1.00) | KDM4CKDM5AKDM2BKDM5BPHF8 | |
| SCHEMBL16033793 | 0.86 | KDM4C (1.00) | KDM4CKDM5AKDM2BKDM5BKDM4A | |
| SCHEMBL16033602 | 0.83 | KDM4C (1.00) | KDM4CKDM5AKDM2BKDM5BKDM4A | |
| SCHEMBL16033516 | 0.83 | KDM4C (1.00) | KDM4CKDM5AKDM2BKDM5BKDM4A | |
| SCHEMBL16033692 | 0.82 | KDM4C (1.00) | KDM4CKDM5AKDM2BKDM5BKDM4A | |
| SCHEMBL16033942 | 0.82 | KDM4C (1.00) | KDM4CKDM5AKDM2BKDM5BKDM4A | |
| SCHEMBL16095229 | 0.82 | KDM4C (0.61) | KDM4CKDM5AKDM2BKDM5BKDM4A | |
| SCHEMBL17898922 | 0.81 | KDM5B (0.63) | KDM4CKDM5AKDM2BKDM5BPHF8 | |
| SCHEMBL16033706 | 0.80 | KDM4C (1.00) | KDM4CKDM5AKDM2BKDM5BKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042905-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM4C 23/4885KDM5A 3/4885KDM2B 5/4885 |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM4C 23/4885KDM5A 3/4885KDM2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.